Comparative Study of Medial-to-Lateral Approach vs Dorsal and Medial Hybrid Approach in Laparoscopic Right Hemicolectomy
Launched by SHANGHAI MINIMALLY INVASIVE SURGERY CENTER · Dec 1, 2017
Trial Information
Current as of June 13, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Aged more then 18 years old;
- • Diagnosed as right hemi colonic cancer with colonoscopic biopsy;
- • Without metastasis;
- • No Invasion of surrounding tissues;
- • Limited operation;
- • Underwent laparoscopic radical right hemicolectomy (L-right hemicolectomy);
- • BMI 18\~30kg/m2;
- • Without multiple primary tumors;
- • Sign on the Medical informed Consent.
- Exclusion Criteria:
- • Simultaneous or simultaneous multiple primary colorectal cancer;
- * Preoperative imaging examination results show:
- • 1. Tumor involves the surrounding organs and combined organ resection need to be done;
- • 2. Distant metastasis;
- • 3. Unable to perform R0 resection;
- • History of any other malignant tumor in recent 5 years;
- • Patients need emergency operation;
- • Not suitable for laparoscopic surgery;
- • Women during Pregnancy or breast feeding period;
- • Informed consent refusal
About Shanghai Minimally Invasive Surgery Center
The Shanghai Minimally Invasive Surgery Center is a leading clinical trial sponsor dedicated to advancing the field of minimally invasive surgical techniques through innovative research and development. With a focus on improving patient outcomes and enhancing recovery times, the center collaborates with healthcare professionals and researchers to conduct rigorous clinical trials that evaluate the safety and efficacy of cutting-edge surgical interventions. Committed to upholding the highest ethical standards and regulatory compliance, the Shanghai Minimally Invasive Surgery Center aims to contribute to the global medical community by translating scientific discoveries into practical applications that benefit patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, Sahgnhai, China
Patients applied
Trial Officials
Minhua Zheng, PhD
Study Director
Ruijin Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials